A randomized, double-blind, placebo-controlled, parallel group study to investigate the effect of ibuprofen on top of multiple doses of 150 microg aleglitazar once daily on renal function, renin-angiotensin system, and pharmacokinetics of both compounds in healthy subjects.

Trial Profile

A randomized, double-blind, placebo-controlled, parallel group study to investigate the effect of ibuprofen on top of multiple doses of 150 microg aleglitazar once daily on renal function, renin-angiotensin system, and pharmacokinetics of both compounds in healthy subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2012

At a glance

  • Drugs Aleglitazar (Primary) ; Ibuprofen
  • Indications Arthritis; Cardiovascular disorders; Pain; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Nov 2012 Results presented at the 85th Annual Scientific Sessions of the American Heart Association.
    • 16 Mar 2012 Actual end date changed from (1 Jun 2011) to (1 Sep 2011) as reported by ClinicalTrials.gov.
    • 19 Sep 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top